Canada Markets close in 5 hrs 39 mins

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
39.54+3.21 (+8.84%)
As of 04:00PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close36.33
Open33.82
Bid36.00 x 1200
Ask36.18 x 800
Day's Range33.49 - 39.78
52 Week Range14.48 - 146.16
Volume2,906,691
Avg. Volume4,726,138
Market Cap1.582B
Beta (5Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-0.56
Earnings DateMar. 21, 2022 - Mar. 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec. 13, 2012
1y Target Est159.25
  • Zacks

    Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs

    Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.

  • Motley Fool

    Where Will Cassava Sciences Be in 1 Year?

    First, the company produced strong results in clinical studies for its potential therapy for Alzheimer's disease (AD), Simufilam. The other reason is the result of Biogen, a competitor, receiving regulatory approval in the U.S. last year for its novel AD treatment -- the first such therapy approved for AD since 2003.

  • Motley Fool

    3 Healthcare Stocks That Could Rocket Higher in 2022

    A key clinical trial, an enormous market opportunity, and breakthrough biotechnology could drive returns for shareholders this year.